- Home
- TRUP vs CNTA Comparison
TRUP vs CNTA Comparison
Compare TRUP & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRUP
- CNTA
- Stock Information
- Founded
- TRUP 2000
- CNTA 2020
- Country
- TRUP United States
- CNTA United Kingdom
- Employees
- TRUP N/A
- CNTA N/A
- Industry
- TRUP Medical Specialities
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- TRUP Health Care
- CNTA Health Care
- Exchange
- TRUP Nasdaq
- CNTA Nasdaq
- Market Cap
- TRUP 1.4B
- CNTA 2.2B
- IPO Year
- TRUP 2014
- CNTA 2021
- Fundamental
- Price
- TRUP $33.58
- CNTA $16.87
- Analyst Decision
- TRUP Buy
- CNTA Strong Buy
- Analyst Count
- TRUP 6
- CNTA 8
- Target Price
- TRUP $46.60
- CNTA $23.17
- AVG Volume (30 Days)
- TRUP 943.1K
- CNTA 1.0M
- Earning Date
- TRUP 05-01-2025
- CNTA 03-27-2025
- Dividend Yield
- TRUP N/A
- CNTA N/A
- EPS Growth
- TRUP N/A
- CNTA N/A
- EPS
- TRUP N/A
- CNTA N/A
- Revenue
- TRUP $1,285,684,000.00
- CNTA $6,853,000.00
- Revenue This Year
- TRUP N/A
- CNTA N/A
- Revenue Next Year
- TRUP $5.05
- CNTA N/A
- P/E Ratio
- TRUP N/A
- CNTA N/A
- Revenue Growth
- TRUP 15.97
- CNTA N/A
- 52 Week Low
- TRUP $19.69
- CNTA $7.75
- 52 Week High
- TRUP $57.90
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- TRUP 35.59
- CNTA 52.95
- Support Level
- TRUP $31.76
- CNTA $15.30
- Resistance Level
- TRUP $34.65
- CNTA $17.29
- Average True Range (ATR)
- TRUP 1.89
- CNTA 1.10
- MACD
- TRUP 0.25
- CNTA 0.11
- Stochastic Oscillator
- TRUP 61.67
- CNTA 67.37
About TRUP Trupanion Inc.
Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue primarily from subscription fees related to the Company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.